AIDS Research and Treatment / 2016 / Article / Tab 2

Research Article

Liver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naïve HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study

Table 2

Clinical and immunological profile of HIV-1 patients at Debre Tabor Hospital, 2013.

VariablesHAART status
On HAART (%)HAART naive (%)

WHO stage
 Stage I34 (20.7)97 (59.1)
 Stage II40 (24.4)44 (26.8)
 Stage III64 (39.0)19 (11.6)
 Stage IV26 (15.9)4 (2.4)

OIs
 No 150 (91.5)134 (81.7)
 Yes14 (8.5)30 (18.3)

BMI (kg/m2)
 <18.539 (23.8)40 (24.4)
 18.5–25113 (68.9)116 (70.7)
 >2512 (7.3)8 (4.9)

HBV
 Negative156 (95.1)152 (92.7)
 Positive8 (4.9)12 (7.3)

HCV
 Negative163 (99.4)162 (98.8)
 Positive1 (0.6)2 (1.2)

Regimen
 1a52 (31.7)
 1b28 (17.1)
 1c40 (24.4)
 1d10 (6.1)
 1e18 (11.0)
 1f16 (9.8)

Hepatotoxicity
 Grade 111 (6.7)17 (10.4)
 Grade 26 (3.7)0
 Grade 35 (3.0)1 (0.6)

WHO: World Health Organization; OI: opportunistic infection; BMI: body mass index; HBV: hepatitis B virus; HCV: hepatitis C virus; HAART: highly active antiretroviral therapy; 1a: d4T+3TC+NVP; 1b: d4T+3TC+ EFV; 1c: AZT+3TC+ NVP; 1d: AZT+3TC+EFV; 1e: TDF+3TC+EFV; 1f: TDF+3TC+NVP.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.